Paired Comparison of PD-L1 Expression on Cytologic and Histologic Specimens from Malignancies in the Lung Assessed with PD-L1 IHC 28-8pharmDx and PD-L1 IHC 22C3pharmDx

Applied Immunohistochemistry and Molecular Morphology

Volumn 25, Issue 7, 2017, Pages 453-459

  Skov, Birgit G ^a   Skov, Torsten ^a  

^a University of Copenhagen   (Denmark)

Author keywords

agreement; cytology; histology; immunohistochemistry; PD L1

Indexed keywords

BIOLOGICAL MARKER; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; CANCER ANTIBODY; CD274 PROTEIN, HUMAN; TUMOR PROTEIN;

AGED; ARTICLE; ASSAY; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; CONTROLLED STUDY; CYTOLOGY; DIAGNOSTIC TEST ACCURACY STUDY; ENDOBRONCHIAL ULTRASONOGRAPHY; ENDOSCOPIC ULTRASOUND GUIDED FINE NEEDLE BIOPSY; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; LARGE CORE NEEDLE BIOPSY; LOBECTOMY; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG CANCER; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MESOTHELIOMA; NEUROENDOCRINE TUMOR; NON SMALL CELL LUNG CANCER; PLEURA EFFUSION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REFERENCE VALUE; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SMALL CELL LUNG CANCER; SQUAMOUS CELL LUNG CARCINOMA; WEDGE RESECTION; BIOSYNTHESIS; CHEMISTRY; GENE EXPRESSION REGULATION; PROCEDURES; STAINING;

AGED; ANTIBODIES, NEOPLASM; B7-H1 ANTIGEN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEOPLASM PROTEINS; STAINING AND LABELING;

EID: 85019674419     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0000000000000540     Document Type: Article

References (24)

1. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627-1639.
2. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018-2028.
3. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540-1550.
4. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823-1833.
5. Vilmann P, Clementsen PF, Colella S, et al. Combined endobronchial and esophageal endosonography for the diagnosis and staging of lung cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline, in cooperation with the European Respiratory Society (ERS) and the European Society of Thoracic Surgeons (ESTS). Endoscopy. 2015;47:545-559.
6. Jose RJ, Shaw P, Taylor M, et al. Impact of EBUS-TBNA on modalities for tissue acquisition in patients with lung cancer. QJM. 2014;107:201-206.
7. Navani N, Nankivell M, Lawrence DR, et al. Lung cancer diagnosis and staging with endobronchial ultrasound-guided transbronchial needle aspiration compared with conventional approaches: an openlabel, pragmatic, randomised controlled trial. Lancet Respir Med. 2015;3:282-289.
8. Tian HY, Xu D, Liu JP, et al. Contribution of ultrasound-guided fine-needle aspiration cell blocks of metastatic supraclavicular lymph nodes to the diagnosis of lung cancer. J Cancer Res Ther. 2015;11 Suppl:C234-C238.
9. Skov BG, Hogdall E, Clementsen P, et al. The prevalence of EGFR mutations in non-small cell lung cancer in an unselected Caucasian population. APMIS. 2015;123:108-115.
10. Ilie M, Long-Mira E, Bence C, et al. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti- PD-L1 therapeutic strategies. Ann Oncol. 2016;27:147-153.
11. Phillips T, Simmons P, Inzunza HD, et al. Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer. Appl ImmunohistochemMol Morphol. 2015;23:541-549.
12. Roach C, Zhang N, Corigliano E, et al. Development of a companion diagnostic PD-L1 immunohistochemistry assay for pembrolizumab therapy in non-small-cell lung cancer. Appl Immunohistochem Mol Morphol. 2016;24:392-397.
13. Hirsch FR, McElhinny A, Stanforth D, et al. PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC Assay Comparison Project. J Thorac Oncol. 2017;12:208-222.
14. Ratcliff MJ, Sharpe A, Midha A, et al. Agreement between programmed cell death ligand-1 diagnostic assays across multiple protein expression cut-offs in non-small cell lung cancer. Clin Cancer Res. 2017. Epub ahead of print.
15. Pyo JS, Kang G, Kim JY. Prognostic role of PD-L1 in malignant solid tumors: a meta-analysis. Int J Biol Markers. 2017;32:e68-e74.
16. Khanna S, Thomas A, Abate-Daga D, et al. Malignant mesothelioma effusions are infiltrated by CD3+ T cells highly expressing PD-L1 and the PD-L1+ tumor cells within these effusions are susceptible to ADCC by the anti-PD-L1 antibody avelumab. J Thorac Oncol. 2016;11:1993-2005.
17. Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10:1243-1260.
18. Food and Drug Administration. Statistical guidance on reporting results from studies evaluating diagnostic tests. Guidance for Industry and FDA Staff. 2007. Available at: https://www.fda.gov/ RegulatoryInformation/Guidances/ucm071148.htm.
19. Bratton L, Russell D, Yong Q, et al. Comparison of PD-L1 immunostaining for non-small cell carcinoma of the lung between paired cytological and surgical specimens. J Am Soc Cytopathol. 2017;5:S48.
20. Scheel AH, Dietel M, Heukamp LC, et al. Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. Mod Pathol. 2016;10:1165-1172.
21. Ilie M, Hofman V, Dietel M, et al. Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients. Virchows Arch. 2016; 468:511-525.
22. Kitazono S, Fujiwara Y, Tsuta K, et al. Reliability of small biopsy samples compared with resected specimens for the determination of programmed death-ligand 1 expression in non-small-cell lung cancer. Clin Lung Cancer. 2015;16:385-390.
23. Casadio C, Guarize J, Donghi S, et al. Molecular testing for targeted therapy in advanced non-small cell lung cancer: suitability of endobronchial ultrasound transbronchial needle aspiration. Am J Clin Pathol. 2015;144:629-634.
24. Jeyabalan A, Bhatt N, Plummeridge MJ, et al. Adequacy of endobronchial ultrasound-guided transbronchial needle aspiration samples processed as histopathological samples for genetic mutation analysis in lung adenocarcinoma. Mol Clin Oncol. 2016;4:119-125.